Analysis Tools
reproductive system
|
• Background Sensitivity: mice exhibit poor fecundity after introgression onto a C57BL/6 background
|
adipose tissue
| N |
• despite the development of dyslipidemia and severe insulin resistance, mice do not develop steatosis or type 2 diabetes
|
|
• mice exhibit hypertrophy and unilocular lipid deposition in mutant brown adipocytes
• however, defects can be prevented by midgestational administration of doxycycline and reverted by a 6 week treatment with doxycycline
|
|
• mice exhibit hypertrophy in mutant brown adipocytes
• however, defects can be prevented by midgestational administration of doxycycline and reverted by a 6 week treatment with doxycycline
|
|
• gonadal fat pads are severely reduced compared to in wild-type mice
• however, defects can be prevented by midgestational administration of doxycycline and reverted by a 6 week treatment with doxycycline
|
|
• mice exhibit 'buffalo humps' comprised of swollen interscapular fat pads due to hypertrophy and unilocular lipid deposition in mutant brown adipocytes
• however, defects can be prevented by midgestational administration of doxycycline and reverted by a 6 week treatment with doxycycline
|
|
• fibrotic white adipose tissue stroma is filled with fragmented lipid droplets and leukocytes
• remaining adipocytes have irregular shapes and range in size from overtly hypertrophic to minuscule cells
• however, defects were prevented by midgestational administration of doxycycline but adipocyte size does not revert following treatment with doxycycline
|
|
• mice lack subcutaneous adipocytes
|
|
• remaining adipocytes have irregular shapes
|
|
• remaining adipocytes range in size from overtly hypertrophic to minuscule cells
|
homeostasis/metabolism
| N |
• despite the development of dyslipidemia and severe insulin resistance, mice do not develop steatosis or type 2 diabetes
|
|
• hyperglycemia develops prepuberty then normalizes latter in life with only sporadic and transient hyperglycemia
• however, treatment with doxycycline reverses metabolic anomalies
|
|
• however, treatment with doxycycline reverses metabolic anomalies
• mice exhibit an increase in serum insulin
|
|
• mice exhibit an increase in serum cholesterol with early onset
• however, treatment with doxycycline reverses metabolic anomalies
|
|
• mice exhibit an increase in serum free fatty acids with early onset
• however, treatment with doxycycline reverses metabolic anomalies
|
|
• mice exhibit an increase in serum triglycerides with early onset
• however, treatment with doxycycline reverses metabolic anomalies
|
|
• mice exhibit severe glucose intolerance
• however, treatment with doxycycline reverses metabolic anomalies
|
endocrine/exocrine glands
|
• mice exhibit pancreas islet cell hyperplasia
• however, treatment with doxycycline reverses metabolic anomalies
|
|
• mice as old as 12 to 18 months exhibit hyperplasia with intact and insulin-laden pancreatic islets with hyperinsulinemia and normoglycemia
|
liver/biliary system
|
• liver size is increased by 60% to 150% and is accompanied by hepatocyte hypertrophy and vacuolization
• however, lipid droplet accumulation is not observed
|
|
• mice exhibit hepatocyte hypertrophy and vacuolization
|
integument
|
• mice lack subcutaneous adipocytes
|
growth/size/body
|
• mice as old as 12 to 18 months exhibit hyperplasia with intact and insulin-laden pancreatic islets with hyperinsulinemia and normoglycemia
|
|
• liver size is increased by 60% to 150% and is accompanied by hepatocyte hypertrophy and vacuolization
• however, lipid droplet accumulation is not observed
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| congenital generalized lipodystrophy type 2 | DOID:0111136 |
OMIM:269700 |
J:125992 | |
| familial partial lipodystrophy | DOID:0050440 |
OMIM:PS151660 |
J:125992 | |
